Pharmacare News Bulletins

Nova Scotia Pharmacare

Pharmacare News Bulletins

The Pharmacare News Bulletins, which are mailed to pharmacies and physicians, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.

Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.

Latest Issues

October Bulletin Vol. 18–06
New Exception Status Benefits: Uptravi (selexipag) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir); New Temporary Benefit: AUVI-Q; Reminder: Claims Submission for Therapeutic Substitution Service – Proton Pump Inhibitors (PPIs) & Valsartan Shortage; and Auditor’s Corner: Reduction in Quantity Dispensed

August Bulletin Vol. 18–05
New Exception Status Benefits: Ibrance (palbociclib) and Erelzi (etanercept); Criteria Updates: Ciprodex (dexamethasone and ciprofloxacin) and Duloxetine (Cymbalta and generic brands); Move to Full Benefit Status: atomoxetine, buprenorphine/naloxone, capecitabine, clopidogrel, and methadone; Therapeutic Substitution Policy Update; Influenza Vaccine Information

July Bulletin Vol. 18-04
Pre-exposure Prophylaxis for HIV

April Bulletin Vol. 18 – 03
New Exception Status Benefits: Lenvima; Criteria Updates for Hepatitis C Medications: Daklinza, Epclusa, Harvoni, Sovaldi, and Zepatier; New Diabetic Product: Single-Let Lancets

March Bulletin Vol. 18 – 02
Nova Scotia Formulary Updates: Changes to Maximum Reimbursable Prices

January Bulletin Vol. 18 – 01
New Exception Status Benefits – Copaxone (glatiramer acetate), Avonex, Rebif (interferon beta-1a), and Betaseron, Extavia (interferon beta-1b); New Products – Cimzia, Revlimid, Sandoz Amlodipine; New Request for Coverage Form – Oral Diabetes Treatments

Latest Issue

October Bulletin Vol. 18–05
New Exception Status Benefits: Uptravi (selexipag) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir); Criteria Updates: Humira (adalimumab), Imbruvica (ibrutinib), and Ibrance (palbociclib); New Temporary Benefit: AUVI-Q

August Bulletin Vol. 18–04
New Exception Status Benefits: Ibrance (palbociclib) and Erelzi (etanercept); Criteria Updates: Ciprodex (dexamethasone and ciprofloxacin) and Duloxetine (Cymbalta and generic brands); Move to Full Benefit Status: atomoxetine, buprenorphine/naloxone, capecitabine, clopidogrel, and methadone.

July Bulletin Vol. 18-03
Pre-exposure Prophylaxis for HIV

April Bulletin Vol. 18-02
New Exception Status Benefits: Lenvima; Criteria Updates for Hepatitis C Medications: Daklinza, Epclusa, Harvoni, Sovaldi, and Zepatier; New Diabetic Product: Single-Let Lancets